The U.S. Food and Drug Administration has approved the first mRNA-based influenza vaccine, marking a major advance in flu prevention. Developed by Moderna, the vaccine is initially approved for adults aged 50 years and older. In a clinical trial involving about 40,000 participants, the mRNA flu vaccine reduced influenza cases by 27% compared with a conventional flu shot. Unlike traditional egg-based vaccines, mRNA vaccines can be produced much faster and updated more quickly if circulating flu strains change. Early research also suggests they may trigger a stronger and longer-lasting immune response, offering improved protection during future flu seasons.
Read more at ScienceNews